PharVision Advisers’s Xylem XYL Stock Holding History

PharVision Advisers’s Portfolio XYL Stock Details XYL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,614	Closed	-$356K	–	662
2025 Q4	$356K	Buy	+2,614	New	+$376K	0.18%	184
2025 Q3	–	Sell	-2,016	Closed	-$261K	–	817
2025 Q2	$261K	Buy	+2,016	New	+$244K	0.37%	118

Other funds holding XYL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

PharVision Advisers's XYL Position: Q1 2026 in Review

PharVision Advisers sold out of Xylem (XYL) in Q1 2026, closing a stake of 2,614 shares — an estimated $356K sold.

PharVision Advisers first reported a position in XYL in Q2 2025 and held it in 2 quarters. The position peaked at $356K in Q4 2025. 1,107 funds tracked by Wall St. Rank hold XYL as of Q1 2026.

PharVision Advisers reported no remaining Xylem position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,614 Xylem shares in Q1 2026, an estimated $356K.
PharVision Advisers first reported a position in Xylem in Q2 2025 and held it in 2 quarters.
PharVision Advisers's Xylem position peaked at $356K in Q4 2025.
1,107 funds tracked by Wall St. Rank held Xylem as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.